Jupiter Neurosciences, Inc. (JUNS)
Jupiter Neurosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Jupiter, FL, US. The stock last traded at $1.24, down 15.41% on the session, giving a market capitalisation of $1.6M. On trailing twelve-month figures it carries a trailing P/E of -0.06, a net margin of -17976.0%. Its beta of 1.85 implies it has historically moved more than the broad market.
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Jupiter Neurosciences, Inc. is most often compared with the following Healthcare names: